ATE393775T1 - Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung - Google Patents

Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung

Info

Publication number
ATE393775T1
ATE393775T1 AT01945484T AT01945484T ATE393775T1 AT E393775 T1 ATE393775 T1 AT E393775T1 AT 01945484 T AT01945484 T AT 01945484T AT 01945484 T AT01945484 T AT 01945484T AT E393775 T1 ATE393775 T1 AT E393775T1
Authority
AT
Austria
Prior art keywords
aplidine
producing
production
new antitumoral
derivatives
Prior art date
Application number
AT01945484T
Other languages
English (en)
Inventor
Ignacio Rodriguez
Concepci N Polanco
Felix Cuevas
Paloma Mendez
Carmen Cuevas
Pilar Gallego
Simon Munt
Ignacio Manzanares
Lopez Maria Teresa Garcia
Rodriguez Marta Gutierrez
Herranz Rosario Herranz
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016148A external-priority patent/GB0016148D0/en
Priority claimed from GB0103750A external-priority patent/GB0103750D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE393775T1 publication Critical patent/ATE393775T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01945484T 2000-06-30 2001-07-02 Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung ATE393775T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016148A GB0016148D0 (en) 2000-06-30 2000-06-30 Synthetic methods for aplidine and new antitiumoral derivatives
GB0103750A GB0103750D0 (en) 2001-02-15 2001-02-15 Synthetic methods for aplidine and new antitumoral derivatives methods of making and using them

Publications (1)

Publication Number Publication Date
ATE393775T1 true ATE393775T1 (de) 2008-05-15

Family

ID=26244577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945484T ATE393775T1 (de) 2000-06-30 2001-07-02 Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung

Country Status (25)

Country Link
US (2) US7348310B2 (de)
EP (1) EP1294747B1 (de)
JP (1) JP5289662B2 (de)
KR (1) KR100866056B1 (de)
CN (2) CN1449408A (de)
AT (1) ATE393775T1 (de)
AU (1) AU6769801A (de)
BR (1) BRPI0112375B8 (de)
CA (1) CA2414609C (de)
CY (1) CY1108549T1 (de)
CZ (1) CZ304204B6 (de)
DE (1) DE60133817T2 (de)
DK (1) DK1294747T3 (de)
ES (1) ES2305083T3 (de)
HK (1) HK1052940B (de)
HU (1) HU228998B1 (de)
IL (2) IL153680A0 (de)
MX (1) MXPA03000202A (de)
NO (1) NO334096B1 (de)
NZ (1) NZ523367A (de)
PL (1) PL208651B1 (de)
PT (1) PT1294747E (de)
SI (1) SI1294747T1 (de)
UA (1) UA76718C2 (de)
WO (1) WO2002002596A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
EP1229922B1 (de) * 1999-11-15 2007-06-06 Pharma Mar, S.A. Behandlung von krebserkrankungen durch aplidin
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
DK1276491T3 (da) 2000-04-07 2007-02-05 Univ Pennsylvania Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
KR20030038812A (ko) 2000-10-12 2003-05-16 파르마 마르, 에스.에이. 암 치료 방법
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
NZ541611A (en) * 2003-03-12 2008-04-30 Dana Farber Cancer Inst Inc Aplidine for multiple myeloma treatment
WO2004084812A2 (en) 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
US20090226465A1 (en) * 2005-10-31 2009-09-10 Jackson David Y Macrocyclic depsipeptide antibody-drug conjugates and methods
MX2008010999A (es) 2006-02-28 2008-09-08 Pharma Mar Sa Tratamientos anti-tumor mejorados.
EP2205263A1 (de) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Verbesserte antitumorbehandlungen
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP2013537181A (ja) * 2010-09-10 2013-09-30 サノフイ 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類
TWI807411B (zh) 2017-04-27 2023-07-01 西班牙商瑪製藥股份有限公司 抗腫瘤化合物
BR112022017008A2 (pt) 2020-03-02 2022-10-11 Pharma Mar Sa Compostos para uso no tratamento de infecção por coronavírus
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
CA3169528A1 (en) 2020-03-02 2021-09-10 Pharma Mar, S.A.U. Pld for use in combination in the treatment of coronavirus
PY2117301A (es) 2020-03-02 2022-08-09 Pharma Mar Sa Compuestos para su uso en infecciones víricas
CN115594739B (zh) * 2021-06-28 2025-02-14 浙江珲达生物科技有限公司 一种dehydrodidemnin B类化合物的制备方法
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) * 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) * 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6509316B2 (en) * 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
ES2102322B1 (es) * 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
JP2001503746A (ja) * 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
WO1998017302A1 (en) * 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Total synthesis of the amino hip analogue of didemnin a
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
AU740598B2 (en) * 1997-05-07 2001-11-08 William J. Crumb Aplidine as an L-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO2000006134A2 (en) * 1998-07-30 2000-02-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
CA2373643A1 (en) 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1229922B1 (de) 1999-11-15 2007-06-06 Pharma Mar, S.A. Behandlung von krebserkrankungen durch aplidin
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
DK1276491T3 (da) * 2000-04-07 2007-02-05 Univ Pennsylvania Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
DE60229414D1 (de) 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
PL360531A1 (en) 2004-09-06
KR20030013477A (ko) 2003-02-14
HU228998B1 (en) 2013-07-29
PL208651B1 (pl) 2011-05-31
CN1449408A (zh) 2003-10-15
BRPI0112375B8 (pt) 2021-05-25
JP2004502702A (ja) 2004-01-29
SI1294747T1 (sl) 2008-12-31
CZ20024233A3 (cs) 2003-06-18
PT1294747E (pt) 2008-08-08
US20080009435A1 (en) 2008-01-10
US7348310B2 (en) 2008-03-25
CA2414609C (en) 2012-04-24
AU6769801A (en) 2002-01-14
IL153680A0 (en) 2003-07-06
HK1052940B (en) 2008-10-24
BR0112375A (pt) 2003-06-24
WO2002002596A3 (en) 2002-05-23
DE60133817D1 (de) 2008-06-12
ES2305083T3 (es) 2008-11-01
DK1294747T3 (da) 2008-10-27
CY1108549T1 (el) 2014-04-09
DE60133817T2 (de) 2009-05-20
CN104650177A (zh) 2015-05-27
BRPI0112375B1 (pt) 2020-12-01
IL153680A (en) 2012-05-31
US20040097413A1 (en) 2004-05-20
EP1294747B1 (de) 2008-04-30
CZ304204B6 (cs) 2014-01-02
NO20026242D0 (no) 2002-12-27
KR100866056B1 (ko) 2008-10-30
NZ523367A (en) 2004-12-24
US7678765B2 (en) 2010-03-16
WO2002002596A2 (en) 2002-01-10
HUP0301387A3 (en) 2005-04-28
EP1294747A2 (de) 2003-03-26
NO20026242L (no) 2003-02-27
CA2414609A1 (en) 2002-01-10
HK1052940A1 (en) 2003-10-03
NO334096B1 (no) 2013-12-09
HUP0301387A2 (hu) 2003-08-28
MXPA03000202A (es) 2003-10-15
JP5289662B2 (ja) 2013-09-11
UA76718C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ATE407987T1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
NO20055741L (no) Nye kjemiske forbindelser
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
ATE497958T1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften
DE50300920D1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
DE50110561D1 (de) Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen
CY1105345T1 (el) Φαινυλαλκινια
DE60107292D1 (de) Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE300534T1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE425143T1 (de) Verfahren zur herstellung von indolen
DE50307320D1 (de) Verfahren zur herstellung von 1,2-dichlorethan mittels direktchlorierung
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
ATE302186T1 (de) Derivate von 3-phenyl-2, 6-dioxopiperidin-3-yl propionamide und verfahren zur deren herstellung
ATE281428T1 (de) Verfahren zur herstellung von methoxyimino- essigsäureamiden
ATE250581T1 (de) Verfahren zur herstellung von 3-cyanopyridin aus 2-methyl-1,5-pentandiamin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1294747

Country of ref document: EP